Groesbeck Investment Management Corp NJ Sells 3,400 Shares of AbbVie Inc. $ABBV

Groesbeck Investment Management Corp NJ decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 51.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,155 shares of the company’s stock after selling 3,400 shares during the quarter. AbbVie comprises approximately 1.4% of Groesbeck Investment Management Corp NJ’s investment portfolio, making the stock its 25th biggest holding. Groesbeck Investment Management Corp NJ’s holdings in AbbVie were worth $731,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Independent Solutions Wealth Management LLC raised its stake in AbbVie by 0.9% during the 3rd quarter. Independent Solutions Wealth Management LLC now owns 13,235 shares of the company’s stock worth $3,064,000 after buying an additional 123 shares during the period. Benjamin Edwards Inc. grew its position in shares of AbbVie by 3.2% in the 3rd quarter. Benjamin Edwards Inc. now owns 386,472 shares of the company’s stock valued at $89,498,000 after purchasing an additional 12,094 shares during the period. Financial Advisory Partners LLC bought a new stake in AbbVie during the 3rd quarter worth approximately $229,000. Compass Financial Group INC SD bought a new stake in AbbVie during the 3rd quarter worth approximately $230,000. Finally, TCV Trust & Wealth Management Inc. raised its holdings in AbbVie by 8.3% during the 3rd quarter. TCV Trust & Wealth Management Inc. now owns 13,242 shares of the company’s stock worth $3,066,000 after buying an additional 1,013 shares during the period. 70.23% of the stock is owned by institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $233.65 on Thursday. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a market cap of $412.95 billion, a P/E ratio of 177.01, a P/E/G ratio of 0.94 and a beta of 0.36. The stock’s 50-day simple moving average is $226.63 and its 200 day simple moving average is $214.80.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is currently 496.97%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Berenberg Bank raised AbbVie to a Buy, providing an analyst-driven demand tailwind that can support near-term share gains. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Multiple reports (WSJ/Reuters) said AbbVie was in advanced talks to acquire Revolution Medicines, fueling takeover speculation that typically lifts a buyer’s stock ahead of any deal announcement. AbbVie Near Deal for Revolution Medicines AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
• Positive Sentiment: AbbVie expanded its oncology pipeline with a first?in?human ABBV?901 trial in ovarian cancer — a pipeline development that supports longer?term growth narratives beyond legacy assets. AbbVie Expands Ovarian Cancer Pipeline With New ABBV?901 Trial
• Neutral Sentiment: Revolution Medicines shares jumped on the takeover rumors (market context), which contributed to intraday volatility in AbbVie-related news flow but doesn’t change AbbVie’s fundamentals unless a deal is announced. Revolution Medicines stock surges over 20%
• Neutral Sentiment: AbbVie scheduled its full?year and fourth?quarter 2025 earnings release and conference call for Feb. 4 — a routine event that will be the next formal opportunity for management to set expectations and move the stock. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Neutral Sentiment: UBS reiterated a Hold rating, highlighting a balanced risk/reward given AbbVie’s premium valuation versus long-duration growth — a reminder that some analysts see limited upside from here. AbbVie: Premium Valuation… Hold Rating
• Negative Sentiment: AbbVie updated guidance: Q4 2025 EPS 3.320–3.360 and FY2025 EPS 10.610–10.650, each nudging slightly under consensus — a conservative tilt that can cap upside and explain some profit?taking. (Company guidance released 1/8/2026)
• Negative Sentiment: After takeover reports, AbbVie publicly denied talks to buy Revolution Medicines, which may roll back some of the acquisition-driven rally and increase short-term volatility. Abbvie denies WSJ report of talks to buy Revolution Medicines
• Negative Sentiment: Competitive pressure: J&J’s Tremfya outspent AbbVie’s Skyrizi on TV ads through December, underscoring intense competition in immunology that can pressure market share and pricing over time. Tremfya outstrips Skyrizi in TV ad spend

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Raymond James Financial set a $256.00 target price on AbbVie in a report on Monday, November 3rd. Piper Sandler reissued an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Finally, Wells Fargo & Company lifted their target price on AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.